Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 238

1.

Prenatal management and timing of delivery of uncomplicated monochorionic monoamniotic twin pregnancy: the MONOMONO study.

Saccone G; MONOMONO working group.

Ultrasound Obstet Gynecol. 2018 Jul 17. doi: 10.1002/uog.19179. [Epub ahead of print]

PMID:
30019431
2.

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.

Renso R, Aroldi A, Pioltelli P, Gambacorti-Passerini C, Elli EM.

Blood Cancer J. 2018 Jun 11;8(6):56. doi: 10.1038/s41408-018-0091-6. No abstract available.

3.

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Piazza R, Magistroni V, Redaelli S, Mauri M, Massimino L, Sessa A, Peronaci M, Lalowski M, Soliymani R, Mezzatesta C, Pirola A, Banfi F, Rubio A, Rea D, Stagno F, Usala E, Martino B, Campiotti L, Merli M, Passamonti F, Onida F, Morotti A, Pavesi F, Bregni M, Broccoli V, Baumann M, Gambacorti-Passerini C.

Nat Commun. 2018 Jun 6;9(1):2192. doi: 10.1038/s41467-018-04462-8.

4.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.

Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ.

Haematologica. 2018 May 17. pii: haematol.2017.171249. doi: 10.3324/haematol.2017.171249. [Epub ahead of print]

5.

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.

Mologni L, Costanza M, Sharma GG, Viltadi M, Massimino L, Citterio S, Purgante S, Raman H, Pirola A, Zucchetti M, Piazza R, Gambacorti-Passerini C.

Neoplasia. 2018 May;20(5):467-477. doi: 10.1016/j.neo.2018.02.009. Epub 2018 Mar 30.

6.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086. [Epub ahead of print]

PMID:
29567798
7.

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, Chiarle R.

Cancers (Basel). 2018 Feb 28;10(3). pii: E62. doi: 10.3390/cancers10030062. Review.

8.

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Khoury HJ, Gambacorti-Passerini C, Brümmendorf TH.

Ann Oncol. 2018 Mar 1;29(3):578-587. doi: 10.1093/annonc/mdy019.

9.

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.

Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM.

Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043. Epub 2018 Feb 8.

10.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH.

J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.

11.

Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.

Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Brümmendorf TH, Su Y, Reisman AL, Shapiro M, Lipton JH.

Cancer. 2018 Feb 1;124(3):587-595. doi: 10.1002/cncr.31082. Epub 2017 Oct 26.

12.

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ.

Am J Hematol. 2017 Nov;92(11):1214-1223. doi: 10.1002/ajh.24887. Epub 2017 Sep 25.

13.

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.

Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Brümmendorf TH, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):684-695.e6. doi: 10.1016/j.clml.2017.06.001. Epub 2017 Jun 17.

14.

Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.

Mologni L, Piazza R, Khandelwal P, Pirola A, Gambacorti-Passerini C.

Am J Hematol. 2017 Oct;92(10):E623-E625. doi: 10.1002/ajh.24865. Epub 2017 Aug 17. No abstract available.

PMID:
28718956
15.

Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes.

Piazza R, Ramazzotti D, Spinelli R, Pirola A, De Sano L, Ferrari P, Magistroni V, Cordani N, Sharma N, Gambacorti-Passerini C.

Sci Rep. 2017 May 22;7:46823. doi: 10.1038/srep46823.

16.

OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes.

Piazza R, Ramazzotti D, Spinelli R, Pirola A, De Sano L, Ferrari P, Magistroni V, Cordani N, Sharma N, Gambacorti-Passerini C.

Sci Rep. 2017 Apr 7;7:46290. doi: 10.1038/srep46290. Erratum in: Sci Rep. 2017 May 22;7:46823.

17.

Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.

Campiotti L, Suter MB, Guasti L, Piazza R, Gambacorti-Passerini C, Grandi AM, Squizzato A.

Eur J Cancer. 2017 May;77:48-56. doi: 10.1016/j.ejca.2017.02.028. Epub 2017 Mar 30. Review.

PMID:
28365527
18.

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.

Mologni L, Magistroni V, Casuscelli F, Montemartini M, Gambacorti-Passerini C.

J Cancer. 2017 Jan 1;8(1):140-145. doi: 10.7150/jca.15838. eCollection 2017.

19.

How "precise" is precision medicine in hematology?

Gambacorti-Passerini C, Piazza R.

Haematologica. 2017 Jan;102(1):4-6. doi: 10.3324/haematol.2016.155267. No abstract available.

20.

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.

Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-Passerini C, Mologni L.

Oncotarget. 2016 Nov 8;7(45):72886-72897. doi: 10.18632/oncotarget.12128.

Supplemental Content

Loading ...
Support Center